• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 05, 2024 at 12:02: AM
via A group of independent experts wasn’t convinced by clinical trial data from company Lykos Therapeutics, which is seeking FDA approval of MDMA-assisted treatment for post-traumatic stress disorder.

article source
 




Top Bottom
Back
Quote